Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC) Meeting Abstract
| Authors: | Albiges, L.; Gurney, H. P.; Atduev, V.; Suarez, C.; Duran, M. A. C.; Pook, D.; Tomczak, P.; Barthelemy, P.; Lee, J. L.; Nalbandian, T.; Stus, V.; Ferguson, T.; Wiechno, P.; Gokmen, E.; Lacombe, L.; Gedye, C.; Perini, R.; Sharma, M.; Li, C.; Lee, C. H. |
| Abstract Title: | Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC) |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1204 |
| End Page: | S1205 |
| Language: | English |
| ACCESSION: | WOS:000866211601704 |
| PROVIDER: | wos |
| DOI: | 10.1016/j.annonc.2022.07.1551 |
| Notes: | Meeting Abstract: 1448O -- Source: Wos |
